Six months of treatment with lanifibranor, Inventiva’s experimental therapy, reduced abnormalities in liver sinusoidal endothelial cells (LSECs) in people with metabolic dysfunction-associated steatohepatitis (MASH),…
News
HEPATITIS
NewsHepatitis E virus can also infect kidney cells: Study
The hepatitis E virus (HEV) has long been known to infect liver cells, but researchers have now shown it is also able to infect…
CHOLANGITIS
NewsNearly half of PBC patients in US haven’t seen a specialist recently
About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…
CHOLESTASIS
NewsRecurrent ICP linked to condition’s severity in 1st pregnancy
Nearly one in three patients diagnosed with intrahepatic cholestasis of pregnancy (ICP) during a first pregnancy will develop the condition again in a subsequent…
FATTY LIVER DISEASE
NewsPemvidutide shows benefit for MASH in Phase 2b clinical trial
Pemvidutide resolved metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, without worsening liver scarring (fibrosis) for more than half of people…
BILIARY ATRESIA
NewsPrenatal ultrasound AI analysis IDs biliary atresia before birth in study
Biliary atresia, a rare liver disease affecting infants, may be diagnosed before birth using a novel artificial intelligence (AI) method that analyzes prenatal ultrasound…
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy of bemnifosbuvir and ruzasvir in people with chronic…
CHOLANGITIS
NewsEMA to review linerixibat for itch in primary biliary cholangitis
The European Medicines Agency (EMA) will review an application for linerixibat, an experimental oral therapy for intense itching associated with primary biliary cholangitis (PBC).
CHOLESTASIS
NewsResearchers develop mutation database, mouse model for PFIC2
Researchers have developed a database of all ABCB11 mutations known to cause progressive familial intrahepatic cholestasis type 2 (PFIC2) and a new mouse model…
FATTY LIVER DISEASE
NewsEMA committee supports Rezdiffra’s OK for fatty liver disease MASH
A committee of the European Medicines Agency (EMA) has granted a positive opinion to Rezdiffra (resmetirom) to treat some people with metabolic dysfunction-associated steatohepatitis (MASH),…
Recent Posts
- For girl in Asia, limited access to genetic testing delayed an Alagille diagnosis
- FDA gives bepirovirsen priority review for chronic hepatitis B
- Starting disease marker levels may shape Iqirvo response in PBC
- The possibility for liver function to improve brings me hope
- New mouse model could help guide PFIC3 treatment research